. A seminal example of this was discovered in the 1920s when Otto Warburg found that cancer cells consume higher levels of glucose and secrete most of the glucose carbon as lactate rather than oxidizing it completely 3, 4 . Since then, studies by multiple groups have uncovered a diverse array of meta bolic changes in cancer, including alterations in glycolytic pathways [3] [4] [5] [6] , the citric acid cycle 7 , glutaminolysis 8, 9 , lipo genesis 10 , lipolysis 11 and proteolysis 12 . These in turn mod ulate the levels of cellular building blocks (lipids, nucleic acids and amino acids), cellular energetics, oncogenic signalling molecules and the extracellular environment to confer protumorigenic and malignant properties.
Despite these advances, our current understanding of cancer metabolism is far from complete and would prob ably benefit from experimental strategies that are capable of profiling enzymatic pathways on a global scale. To this end, conventional genomic 13, 14 and proteomic [15] [16] [17] [18] meth ods, which comparatively quantify the expression levels of transcripts and proteins, respectively, have yielded many useful insights. These platforms are, however, lim ited in their capacity to identify changes in protein activ ity that are caused by posttranslational mechanisms 19 . Annotating biochemical pathways in cancer is further complicated by the potential for enzymes to carry out dis tinct metabolic activities in tumour cells that might not be mirrored in normal physiology. In addition, a substantial proportion of the human proteome remains functionally uncharacterized, and it is likely that at least some of these poorly understood proteins also have roles in tumori genesis. These challenges require new proteomic tech nologies that can accelerate the assignment of protein function in complex biological systems, such as cancer cells and tumours. In this Review, we discuss one such proteomic platform, termed activitybased protein profil ing (ABPP) [20] [21] [22] , and its implementation in the discovery and functional characterization of deregulated enzymatic pathways in cancer. We discuss the evidence that, when coupled with other largescale profiling methods, such as metabolomics 23, 24 and proteomics [15] [16] [17] [18] , ABPP can provide a compelling, systemslevel understanding of biochemi cal networks that are important for the development and progression of cancer.
ABPP for enzyme discovery in cancer ABPP uses active sitedirected chemical probes to directly assess the functional state of large numbers of enzymes in native biological samples (FIG. 1) . Activitybased probes consist of at least two key elements: a reactive group for binding and covalently labelling the active sites of many members of a given enzyme class (or classes), and a reporter tag for the detection, enrichment and identifi cation of probelabelled enzymes in proteomes. Activity based probes can be adapted for in situ or in vivo labelling by substituting the reporter tag with a bio-orthogonal chemical handle, such as an alkyne. Probelabelled enzymes are then detected by subsequent click chemistry conjugation to various azidemodified reporter tags 25, 26 . There are currently activitybased probes for a multitude of enzyme classes, including many that have central roles in cancer, such as hydrolases and proteases 20, [27] [28] [29] [30] [31] [32] [33] [34] , kinases [35] [36] [37] [38] , phos phatases 39 , histone deacetylases 40, 41 , glycosidases 42, 43 and various oxidoreductases 44, 45 . ABPP can be applied to vir tually any cell or tissue (assuming that the genome of the parental organism has been sequenced) and can be com bined with a range of analytical methods for data acquisi tion, including gel and mass spectrometry (mS)based methods 21 . Although the specificity of ABPP probes is not absolute, and these probes can be toxic and disrupt bio chemical pathways when applied to living systems, they are of great value for characterizing deregulated enzymatic activities in various cancer models and specimens, as dis cussed below. examples of activitybased probes that have been used in cancer studies are provided in TABLE 1. Serine hydrolases are one of the largest and most diverse enzyme classes in mammalian proteomes and include esterases, thioesterases, lipases, amidases and proteases 46 . Several serine hydrolases have been impli cated in tumorigenesis, including fatty acid synthase 10 , protein methyl esterase 1 (REF. 47 ), and urokinasetype (uPA) and tissuetype (tPA) plasminogen activators 48 . Fluorophosphonate probes that target the serine hydro lase superfamily 20, 27, 28 (TABLE 1) have been used to discover several deregulated enzymes in cancer [49] [50] [51] [52] . using ABPP, we discovered that two serine hydrolases -the uncharac terized enzyme KIAA1363 (REFs 49, 52, 53) and monoacyl glycerol (mAG) lipase (mAGl) 11 -are highly expressed in aggressive human cancer cells and primary tumours. We also used ABPP to develop selective inhibitors of KIAA1363 and mAGl for the functional characteriza tion of these enzymes in cancer (discussed below ; FIG. 2 ). using ABPP, Shields and colleagues 54 recently determined that the activity of the serine hydrolase retinoblastoma binding protein 9 (RBBP9) is increased in pancreatic car cinomas, in which it promotes anchorageindependent growth and pancreatic carcinogenesis through overcom ing transforming growth factorβ (TGFβ)mediated anti proliferative signalling by reducing the phosphorylation levels of SmAD2 and SmAD3.
ABPP has also contributed to our knowledge of serine protease activities in cancer. In the course of characteriz ing an in vivoderived variant of the human breast cancer line mDAmB231, termed 231mFP cells, we determined that these cells possess increased uPA and tPA activity in their secreted proteome 51 . These cells also show increased tumour growth in vivo, suggesting that deregulated proteolytic activity could contribute to their increased pathogenicity. madsen and colleagues 55 compared ser ine hydrolase activities in high and low intravasating variants of the human fibrosarcoma HT1080 cell line and found increased uPA activity in the highintrava sating variant, in which the protease controlled tumour cell intravasation. Interestingly, in these examples, altera tions in protease activity occurred without significant changes in mRNA 51 or protein 55 expression. Interrogating the activities of other protease families has also provided new insights into deregu lated proteolytic processes in cancer. using epoxide electrophile probes for cysteine proteases 56 (TABLE 1), Joyce and colleagues 57 found that cathepsin activity is higher in angiogenic vasculature and at the invasive fronts of carcinomas, and that pharmacological ablation of a wide range of cathepsins impaired the angiogenic switch, tumour growth, vascularity and invasiveness. They also found that cysteine cathepsins are increased in human papilloma virus (HPV)induced cervical carcinomas 57 . Profiling metalloproteinase activities with photoreac tive, hydroxamate activitybased probes (TABLE 1) has uncovered neprilysin as a membraneassociated glyco protein that has increased activity in aggressive human melanoma lines compared with lessaggressive counter parts 31 . Comparison of ubiquitinspecific protease activi ties using the haemagglutinintagged ubiquitinvinyl methyl ester probe (TABLE 1) revealed that the deubiq uitylases ubiquitincarboxyl esterasel3 (uCHl3) and uCH37 were upregulated in HPVpositive tumours com pared with adjacent normal cervical tissue 58 .
Comparison of a heptaoma cell line that expressed a stably replicat ing hepatitis C virus subgenomic replicon RNA with the parental cell line using ABPP probes composed of an Nacetylated amino acid that mimicked the P1 position in the peptide substrates of the protease, identified several differentially regulated enzyme activities, some of which were decreased or increased during HCV replication 59 . ABPP has also been used for imaging enzyme activi ties. Bogyo and colleagues 60 have introduced quenched nearinfrared fluorescent activitybased probes (qNIRF ABPs) to image cysteine protease activities in tumour xenografts in vivo and ex vivo. These probes emit a fluo rescent signal only after covalently modifying a specific protease target, and they can also be used to monitor smallmolecule inhibition of protease targets both bio chemically and by direct imaging methods. The same researchers have implemented a similar approach using a highly selective azapeptidyl asparadinyl epoxide qNIRF ABP 61 to target a specific lysosomal cysteine protease, legumain, the expression of which is increased in many human cancers. In another study, mice were treated with dexamethasone, which induced apoptosis and caspase activation in the thymus, both of which were visualized in vivo using a caspasedirected activitybased probe 62 (TABLE 1) . This probe could also detect apoptosis that was induced by the monoclonal antibody Apomab in mice bearing xenografted human colorectal tumours 62 . Further more, Blum and colleagues 63 demonstrated that among contrast agents for protease activities (small peptides,
At a glance
• Activity-based protein profiling (ABPP) facilitates the discovery of deregulated enzymes in cancer.
• Competitive ABPP yields selective inhibitors for functional characterization of cancer enzymes.
• ABPP can be integrated with metabolomics to map deregulated enzymatic pathways in cancer.
• ABPP can be integrated with other proteomic methods to map proteolytic pathways in cancer.
• ABPP probes can be used to image tumour development in living animals. large polymerbased quenched fluorescent substrates and fluorescently labelled ABPP probes), fluorescent ABPP probes showed more rapid and selective uptake into tumours and overall brighter signal compared with sub stratebased probes. These approaches can potentially be used in the clinic to define tumour margins, diagnose tumour grade and assess drugtarget occupancy in vivo.
ABPP for inhibitor discovery in cancer
Because activitybased probes label the active sites of their enzyme targets, they can form the basis for a competi tive screen for enzyme inhibitors 27, 64, 65 . This competitive ABPP platform has several advantages compared with conventional substrate assays, as inhibitor screens can be conducted directly in complex proteomes and allow concurrent optimization of potency and selectivity against many enzymes in parallel (FIG. 1) . Inhibitors can also be developed for uncharacterized enzymes that lack known substrates 53, 66 . Beyond its important role in inhibitor discovery, competitive ABPP has been used to identify drug targets and offtargets in preclinical or clinical devel opment to gauge mechanism of action and safety 31, 37, 67, 68 . Competitive ABPP has served as a principal assay for screening directed libraries of inhibitors and for optimizing their selectivity against serine hydrolases that are expressed in cancer cell and tissue proteomes. This effort has led to the identification of two carbamate agents, AS115 (REF. 53) and JZl184 (REF. 69 ), which are potent and selective inhibi tors of KIAA1363 and mAGl, respectively. Competitive ABPP has also been used to explore the full target profile for anticancer drugs. Profiling cytochrome P450 enzymes with clickable arylalkyne probes (TABLE 1) showed that the aromatase inhibitor anastrazole, which is approved for breast cancer therapy, significantly increases the activity (as determined by probe labelling) of CYP1A2 and decreases the activity of CYP2C19 (REF. 68 ). These results indicate that anastrazole interacts with multiple P450 enzymes and, in at least one case (CYP1A2), might cooperatively . In a typical ABPP experiment, a proteome is reacted with the activity-based probe and probe-labelled proteins detected by either in-gel fluorescence scanning (for fluorophore-conjugated probes; top) or avidin enrichment, on-bead tryptic digest and liquid chromatograpy-mass spectrometry (LC-MS) analysis (for biotinylated probes; bottom). b | ABPP can also be used in a competitive format to evaluate the potency and selectivity of enzyme inhibitors in native biological samples. Inhibitors compete with activity-based probes for enzyme targets, and this competition is read out by loss of fluorescence (for fluorophore-conjugated probes) or MS (for biotinylated probes) signals (not shown). m/z, mass to charge ratio.
enhance the binding of other drugs. Characterization of the matrix metalloproteinase (mmP)directed inhibi tor Gm6001 (ilomastat) by competitive ABPP revealed that this agent also inhibits several metalloproteinases outside of the mmP family 31 , which could explain some of the toxicity issues that broadspectrum mmP inhibi tors have confronted in clinical development 70 . Kinase directed activitybased probes (TABLE 1) have been used to identify 39 kinase targets of the broadspectrum inhibitor staurosporine in cancer cell lines 35 . Activitybased probes based on the structure of the PI3K inhibitor wortmannin 37, 38 , revealed that this natural product also targets members of the pololike clan of kinases 37, 71 . The integration of competitive ABPP platforms into the pre clinical and clinical development of cancer therapeutics has the potential to clarify the mechanism of action and reduce offtarget toxicity for future drug candidates.
Finally, we should note that competitive ABPP experiments have historically been analysed using onedimensional (1D) SDS-PAGe or mS, which are 11, 49 . Identified increased uPA and tPA serine protease activities in secreted proteomes of aggressive cancer cells 51, 52 . Identified increased RBBP9 activity in pancreatic carcinomas 54 Metalloproteinases Identified increased neprilysin activity in aggressive melanoma cell lines 31 Cysteine proteases Identified increased cathepsin cysteine protease activities in pancreatic islet tumours 57 . Used for in vivo imaging of tumour cathepsin activity 57, 60 Kinases
Inhibitor selectivity profiling of kinase inhibitors 35, 71 Caspases , which provides a homogeneous assay that is compatible with highthroughput screening and which can be adapted to different classes of enzymes and activitybased probes. FluopolABPP has been suc cessfully used to discover selective inhibitors for two cancerrelated enzyme targets, the hydrolytic enzyme RBBP9 and the thioltransferase glutathione Stransferase omega 1 (GSTO1) 72, 73 .
Integration of ABPP with other profiling methods
Integration of ABPP with metabolomics. metabolomics has emerged as a powerful method for broadly assess ing the biochemical functions of enzymatic pathways in normal physiology and disease 23, 24 
. When com plemented with selective inhibitors developed through competitive ABPP, metabolomics can be used to not only identify endogenous substrates and products of enzymes, but also metabolites that are upstream or downstream of these immediate substrates and products, allowing the integration of individual enzymatic reactions into the larger metabolic networks of cancer cells. Two examples of how coupling of ABPP with metabolomics has helped in defining contributions made by enzymes in cancer are discussed below.
A role for KIAA1363 in regulating pro-tumorigenic ether lipids. As mentioned above, ABPP studies iden tified increased KIAA1363 activity in both aggressive human cancer cell lines 53 and primary tumours 49 , and have identified AS115 as a potent and selective inhibi tor of this enzyme 53 . untargeted liquid chromatograpy (lC)-mS analysis of lipophilic metabolites from AS115 treated cancer cells revealed that KIA1363 regulates an unusual class of lipids -the monoalkylglycerol ethers (mAGes) 11 . Previous studies had shown that tumours contained increased levels of mAGe and other ether lipids and identified positive correlations between ether lipid content and tumorigenicity in cancer cells 74, 75 . However, the enzymes that regulate ether lipid metabolism in can cer have remained enigmatic. Additional studies showed that KIAA1363 is the principal 2acetyl mAGe hydro lase in cancer cells, providing one potential pathway by which this enzyme could influence ether lipid content. Importantly, stable knock down of KIAA1363 by RNA interference (RNAi) also led to a reduction in mAGe levels, and this effect was found to further perturb other protumorigenic lipids, including alkyl lysophosphatidic acid (alkyllPA) 53 . These metabolic changes in cancer cells correlated with reductions in migration and in vivo tumour growth, thus pointing to an important role for the KIAA1363-ether lipid pathway in supporting cancer pathogenesis 53 .
A role for MAGL in regulating fatty acid pathways in cancer cells. Competitive ABPP identified a potent and selective mAGl inhibitor, JZl184 (REF. 69 ), which increases mAG levels in multiple tissues in mice with out concurrent changes in global free fatty acid levels 76 . In contrast to this metabolic profile, mAGl inhibition in aggressive melanoma cells, and ovarian and breast cancer cells, not only raised mAGs but also lowered free fatty acid levels -results that were confirmed by RNAi knock down of mAGl 11 . mAGl reductions also impaired cancer cell migration, invasion and serumfree cell survival in vitro, as well as tumour xenograft growth in vivo 11 . These effects were rescued by the addition of free fatty acids in vitro or treatment with a highfat diet in vivo, which supports a protumorigenic role for mAGlgenerated fatty acids. Also consistent with this premise, overexpression of wildtype, but not catalyti cally dead, mAGl was sufficient to increase free fatty acids and confer malignant properties on nonaggressive cancer cells 11 . metabolomic profiles revealed that the mAGl-fatty acid pathway feeds into a larger lipid network that includes the protumorigenic signalling molecules lPA and prostaglandin e 2 (PGe 2 ) 11 . These results suggest that as tumour development progresses, cancer cells with increased mAGl activity produce more cellular fatty acids, which can serve as building blocks for lipid transmitters that further drive cancer malignancy.
Additional metabolomic studies in cancer. metabolomics has also been a useful technology for characterizing enzymes that are genetically mutated in cancer. An inte grated genomic analysis, consisting of sequencing 22,661 proteincoding genes coupled with highdensity oligonu cleotide array analysis of 22 human glioblastoma (World Health Organization (WHO) grade IV) samples, identified mutations in the enzyme cytosolic isocitrate dehydroge nase 1 (IDH1) as a common feature of a major subset of primary human brain cancers 7 . These mutations produce a single amino acid change in the IDH1 active site, resulting in the loss of the ability of the enzyme to convert isocitrate to αketoglutarate. metabolomics revealed that cancer associated mutations also result in a new catalytic activity -the NADPHdependent reduction of αketoglutarate to R(2)2hydroxyglutarate (2HG) 7 . Human malignant glio mas with an IDH1 mutation exhibit markedly increased levels of 2HG compared with gliomas without this muta tion 7 . These intriguing findings designate 2HG as a poten tial oncometabolite. Consistent with this hypothesis, an excess accumulation of 2HG has been shown to lead to an increased risk of brain tumour development in patients with inborn errors of 2HG metabolism 77 .
ABPP and proteases.
Proteases have long been implicated as drivers of tumorigenesis and are important for early tumour progression, as well as invasion and meta stasis [78] [79] [80] [81] . Increased protease activity is also useful as a diagnostic marker for many cancers [78] [79] [80] [81] . Although pro teases catalyse one of the most pervasive posttranslational modifications in living systems, most of these enzymes remain incompletely characterized with respect to their endogenous substrates. Whereas technologies such as ABPP are useful for identifying deregulated proteolytic activities, additional methods are required to identify
Box 1 | Metabolomics
Metabolomics has emerged as a powerful approach for investigating enzyme function in living systems 23, 24 . Metabolomic experiments in the context of enzyme studies typically start with the extraction of metabolites from control and enzyme-disrupted biological systems, followed by metabolite detection and comparative data analysis. For example, lipophilic metabolites can be enriched from cells or tissues by organic extraction. Mass spectrometry (MS) has become a primary analytical method for surveying metabolites in complex biological samples, with upfront separation accomplished by liquid chromatography (LC-MS) or gas chromatography (GC-MS). MS experiments can be carried out using targeted 92 or untargeted 93, 94 approaches, depending on whether the objective is to profile and quantitate known metabolites or to broadly scan for metabolites across a large mass range, respectively. As metabolomic experiments generate a large amount of data, powerful software tools are needed for identification and quantitation of ions in LC-MS data sets (see the figure; the mass to charge ratio (m/z) is indicated). One such program is XCMS 95 , which aligns, quantifies and statistically ranks ions that are altered between two sets of metabolomic data. This program can be used to rapidly identify metabolomic signatures of various disease states or to assess metabolic networks that are regulated by an enzyme using pharmacological or genetic tools that modulate enzyme function. Additional databases assist in metabolite structural characterization, such as HMDB 96, 97 , METLIN 98, 99 and LIPID MAPS 100 . the substrates of proteases. To address this issue, several proteomic approaches have been developed that glo bally profile protease-substrate relationships in native biological systems [82] [83] [84] [85] [86] (FIG. 3) . One group of proteomic methods, Nterminal labelling techniques, relies on chemically tagging neoN termini that are produced through proteolytic cleavage events. The chemically tagged Nterminal peptides can then be enriched and analysed using mS methods. many variations of this strategy have been developed and have been instru mental in identifying exact sites of proteolytic cleavage for various proteases, including caspases 84 and mmPs 85 . Wells and colleagues 84 have introduced an engineered enzyme (subtiligase) to tag and enrich nascent N ter mini in complex protein mixtures. Application of this technique to study apoptosis led to the identification of 292 caspasecleaved proteins 84 . Overall and colleagues 85 have recently developed the terminal amine isotopic labelling of substrates (TAIlS) technique, which uses an aminereactive polymer to capture internal peptides leaving only labelled neoN termini and mature blocked N termini for mS analysis. They used this technique to extensively study the substrate profile of mmP2 in mouse fibroblast secretomes and identified 288 poten tial substrates for this protease 85 . Van Damme et al. 82 developed an Nterminal enrichment strategy, which relies on combined fractional diagonal chromatography (COFRADIC), and so identified 93 caspasemediated cleavage events during CD95induced apoptosis. Also of note is the NClAP method developed by Jaffrey and colleagues 83 , which uses a chemical treatment strategy to selectively label Nterminal amines on proteins.
R E V I E W S
Although Nterminal labelling methods have provided valuable insights into biological systems that are controlled by proteases, they possess some drawbacks. Perhaps most notably, the identification of a cleavage event relies on the detection of a single peptide from the Cterminal portion of a cleaved protein, and therefore does not provide infor mation on the size or stability of the remaining protein fragments. With this consideration in mind, we developed a platform for protease substrate discovery that aims to provide a more complete topological map of proteolytic events occurring in biological systems. This approach, termed the Protein Topography and migration Analysis Platform (PROTOmAP), consists of the fractionation of active and inactive protease samples by 1D SDS-PAGe, followed by lC-mS analysis of tryptically digested pro teins from individual gel bands 86, 87 (FIG. 3) . Identified proteins are subsequently assembled into twodimensional peptographs that combine sequence coverage with gel migration information, and when coupled with spec tral counting data this yields a semiquantitative topo graphical map for all detectable proteins (and their cleavage products) in a sample. PROTOmAP has been used to study the intrinsic apoptotic pathway in Jurkat T cells, resulting in the discovery of more than 250 protein cleavage events in apoptotic cells, most of which had not previously been reported in the literature 86, 87 . Interestingly, ) or, alternatively, the internal unmodified peptides can be removed through negative selection methods (such as terminal amine isotopic labelling of substrates (TAILS) methods 85 ). The remaining pool of enriched labelled neo-N termini can then be analysed using tandem mass spectrometry (MS) and the exact sites of proteolytic cleavage can be assigned. b | An alternative proteomic method for protease substrate identification, Protein Topography and Migration Analysis Platform (PROTOMAP 86 ) combines one-dimensional (1D) SDS-PAGE fractionation with liquid chromatograpy (LC)-MS analysis. In a typical PROTOMAP experiment, proteomes from control (Ctrl; red) and experimental (protease-active) (Expt; blue) systems are separated by 1D SDS-PAGE. The lanes are cut into bands at fixed intervals, digested with trypsin and analysed by LC-MS/MS to generate data that are integrated into peptographs, which plot sequence coverage for a given protein in the horizontal dimension (N to C terminus; left to right) versus gel migration in the vertical dimension. Spectral count values for each protein in each gel band provide quantitation. Cleaved proteins are identified by shifts in migration from higher to lower molecular weight (MW) in Ctrl versus Expt systems. a metaanalysis has revealed substantial congruency in the proteolytic events identified by the subtiligase and PROTOmAP methods in apoptotic cells 73 , indicating that these approaches provide complementary ways to charac terize proteolytic pathways in biological systems. We envi sion that coupling protease-substrate discovery platforms with ABPP should offer a versatile and a potentially rou tine way to map deregulated proteolytic pathways in cancer and other pathophysiological processes. The information acquired by protease-substrate discovery platforms should also guide the development of new substratederived ABPP probes for specific proteases.
Conclusions
Chemical labelling methods have become centrepieces for a wide range of proteomic investigations, whether for measuring the expression 88 and the posttranslational modification [89] [90] [91] of proteins or, as we discuss above, the activity state of proteins. We have attempted to highlight how one such chemoproteomic technology, ABPP, has enabled the discovery of new enzyme activities deregu lated in human cancer. Importantly, ABPP also provides a builtin assay that can be used to develop inhibi tors to assess the functional role of enzymes in cancer. Activitybased probes have found additional uses as, for example, imaging agents to visualize enzyme activities in tumours. An extension of these studies into a clinical set ting could enable rapid imaging, staging and diagnosis of various types of cancers both in biopsy samples and in vivo. looking forwards, we also anticipate that ABPP might have an important role in demystifying the process of target identification for chemical genomic screens in cancer cells. lead compounds emerging from phenotypic screens could be transformed into ABPP probes by intro ducing, for example, photoreactive groups and clickable affinity handles to facilitate the identification of protein targets and sites of probe labelling.
With the advent of fluopolABPP, inhibitor dis covery and optimization can now be carried out in a highthroughput manner, allowing cancerrelevant enzyme targets to be screened against extensive small molecule libraries, such as those available as part of the uS National Institutes of Healthsupported molecular libraries Screening initiative. By coupling ABPP with other largescale profiling methods, such as metabo lomics and proteomics, important insights can be gained into how certain enzymes are used or hijacked to carry out biochemical tasks that fuel tumorigenesis. Such enzymes could be important targets for the next generation of cancer therapeutics.
